Aequs Shares Crash 19% After September-Quarter Loss Widens to Rs 52.3 Crore and EBITDA Drops 45%

The Quick Take

• Aequs shares fell 19% after Q2 FY27 (September quarter) results showed a net loss widening to Rs 52.3 crore and EBITDA plunging 45%, even as revenue grew 45.3% to Rs 409.1 crore.
• The company maintains a $1.1 billion aerospace manufacturing order, underscoring the strength of its institutional aerospace business despite consumer segment losses weighing on profitability.
• Mint Markets asked analysts whether investors should buy, sell, or hold — with the answer hinging on whether the strong aerospace pipeline justifies holding through consumer business losses.

Aequs Q2 FY27 (September quarter) delivered a set of numbers that illustrate the bifurcated nature of the business. Revenue grew 45.3% to Rs 409.1 crore — an impressive top-line expansion. But EBITDA dropped 45% and the net loss widened to Rs 52.3 crore, creating a scenario where rapid revenue growth is coexisting with deteriorating profitability. This pattern is characteristic of a company investing aggressively — in capacity, headcount, or marketing — at a rate that exceeds current revenue generation capacity. The $1.1 billion aerospace manufacturing order provides the strategic context: Aequs appears to be investing in manufacturing capacity to execute large aerospace contracts whose revenue will likely materialise over multi-year timelines.

The buy-sell-hold debate that Mint Markets frames is essentially a question of patience capital: can investors hold through the loss-making investment phase long enough to reach the point where aerospace contract deliveries generate positive EBITDA? The aerospace business, serving global OEMs in commercial aviation and defence, typically requires 2-3 years of capacity investment before the order book converts to cash-generative deliveries at scale. Aequs's $1.1 billion order provides the contractual certainty that aerospace revenue will eventually scale — but the timeline and the extent to which consumer losses will have consumed shareholder capital by then is the key uncertainty.

Aequs investors face a binary narrative from here: either the consumer business EBITDA breakeven comes within 2 quarters and the aerospace ramp begins to offset losses (buy case), or consumer breakeven extends and capital consumption continues, requiring further equity raises that dilute existing holders (sell or hold case). The operative numbers to watch are consumer EBITDA margin (quarterly improvement from -45% would signal recovery), Aequs's cash and borrowing facilities (runway indicator), and aerospace delivery milestones against the $1.1 billion order. Any capex commitment reduction — as alluded to in CNBC's interview — would be a sign of prioritising aerospace over consumer, which is actually the more defensible strategy.

Synthesized from 1 source.